CRISPR Therapeutics promotes Andrew Silver to CFO as Raju Prasad resigns
CRISPR Therapeutics AG
Andrew J. Silver, 42, was promoted to Chief Financial Officer effective October 19, 2026; he will serve as principal financial and accounting officer.
Silver's annual salary is $515,000 with a 45% target bonus and a one-time grant of 25,000 restricted stock units vesting on the second anniversary.
Raju Prasad, Ph.D. resigned as CFO to pursue external opportunities; CRISPR said the resignation was not due to any disagreement and he is expected to stay until on or before November 30, 2026.
The employment agreement provides six months' notice for involuntary departure, or 12 months plus equity acceleration within 12 months after a Change in Control.
On October 19, 2026, CRISPR Therapeutics AG (the “Company”) announced the promotion of Andrew J. Silver, currently the Company’s SVP, Finance, to be the Company’s Chief Financial Officer effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Andrew J. Silver changed role as Chief Financial Officer at CRISPR Therapeutics AG.
Action
promoted
Role
Chief Financial Officer
Exact text from the filing
On October 19, 2026, CRISPR Therapeutics AG (the “Company”) announced the promotion of Andrew J. Silver, currently the Company’s SVP, Finance, to be the Company’s Chief Financial Officer effective immediately.
This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.